221 related articles for article (PubMed ID: 22015149)
21. Etanercept: efficacy and safety.
Jiménez-Puya R; Gómez-García F; Amorrich-Campos V; Moreno-Giménez JC
J Eur Acad Dermatol Venereol; 2009 Apr; 23(4):402-5. PubMed ID: 19210697
[TBL] [Abstract][Full Text] [Related]
22. Initial experience with routine administration of etanercept in psoriasis.
de Groot M; Appelman M; Spuls PI; de Rie MA; Bos JD
Br J Dermatol; 2006 Oct; 155(4):808-14. PubMed ID: 16965432
[TBL] [Abstract][Full Text] [Related]
23. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis.
Ortonne JP; Paul C; Berardesca E; Marino V; Gallo G; Brault Y; Germain JM
Br J Dermatol; 2013 May; 168(5):1080-7. PubMed ID: 23013207
[TBL] [Abstract][Full Text] [Related]
24. Patients with psoriasis respond to continuous open-label etanercept treatment after initial incomplete response in a randomized, placebo-controlled trial.
Krueger GG; Elewski B; Papp K; Wang A; Zitnik R; Jahreis A
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S112-9. PubMed ID: 16488321
[TBL] [Abstract][Full Text] [Related]
25. Etanercept use for psoriasis in Taiwan: a case series study.
Chiu HY; Wang TS; Cho YT; Tsai TF
Int J Dermatol; 2013 Jun; 52(6):673-80. PubMed ID: 22348620
[TBL] [Abstract][Full Text] [Related]
26. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years.
Lebwohl M; Blum R; Berkowitz E; Kim D; Zitnik R; Osteen C; Wallis WJ
Arch Dermatol; 2005 Jul; 141(7):861-4. PubMed ID: 16027301
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis.
Weinblatt ME; Bathon JM; Kremer JM; Fleischmann RM; Schiff MH; Martin RW; Baumgartner SW; Park GS; Mancini EL; Genovese MC
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):373-82. PubMed ID: 20957659
[TBL] [Abstract][Full Text] [Related]
28. Multiple squamous cell carcinomas in the setting of psoriasis treated with etanercept: a report of four cases and review of the literature.
Brewer JD; Hoverson Schott AR; Roenigk RK
Int J Dermatol; 2011 Dec; 50(12):1555-9. PubMed ID: 22098006
[TBL] [Abstract][Full Text] [Related]
29. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis.
Moore A; Gordon KB; Kang S; Gottlieb A; Freundlich B; Xia HA; Stevens SR
J Am Acad Dermatol; 2007 Apr; 56(4):598-603. PubMed ID: 17113190
[TBL] [Abstract][Full Text] [Related]
30. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials.
Gordon KB; Papp KA; Langley RG; Ho V; Kimball AB; Guzzo C; Yeilding N; Szapary PO; Fakharzadeh S; Li S; Hsu MC; Reich K
J Am Acad Dermatol; 2012 May; 66(5):742-51. PubMed ID: 21978572
[TBL] [Abstract][Full Text] [Related]
31. Etanercept reduces symptoms and severity of psoriasis after cessation of cyclosporine therapy: results of the SCORE study.
Micali G; Wilsmann-Theis D; Mallbris L; Gallo G; Marino V; Brault Y; Germain JM
Acta Derm Venereol; 2015 Jan; 95(1):57-61. PubMed ID: 24682319
[TBL] [Abstract][Full Text] [Related]
32. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial.
Gisondi P; Del Giglio M; Cotena C; Girolomoni G
Br J Dermatol; 2008 Jun; 158(6):1345-9. PubMed ID: 18410408
[TBL] [Abstract][Full Text] [Related]
33. [Long-term safety and efficacy of etanercept in the treatment of psoriasis].
Zaragoza V; Pérez A; Sánchez JL; Oliver V; Martínez L; Alegre V
Actas Dermosifiliogr; 2010; 101(1):47-53. PubMed ID: 20109392
[TBL] [Abstract][Full Text] [Related]
34. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept monotherapy at 6 weeks.
Gambichler T; Tigges C; Scola N; Weber J; Skrygan M; Bechara FG; Altmeyer P; Kreuter A
Br J Dermatol; 2011 Jun; 164(6):1383-6. PubMed ID: 21466532
[TBL] [Abstract][Full Text] [Related]
35. Rates of serious infections, opportunistic infections, inflammatory bowel disease, and malignancies in subjects receiving etanercept vs. controls from clinical trials in ankylosing spondylitis: a pooled analysis.
van der Heijde D; Zack D; Wajdula J; Sridharan S; Koenig AS
Scand J Rheumatol; 2014; 43(1):49-53. PubMed ID: 24182312
[TBL] [Abstract][Full Text] [Related]
36. Etanercept combined with methotrexate for high-need psoriasis.
Driessen RJ; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2008 Aug; 159(2):460-3. PubMed ID: 18547310
[TBL] [Abstract][Full Text] [Related]
37. Utilization of narrow-band ultraviolet light B therapy and etanercept for the treatment of psoriasis (UNITE): efficacy, safety, and patient-reported outcomes.
Kircik L; Bagel J; Korman N; Menter A; Elmets CA; Koo J; Yang YC; Chiou CF; Dann F; Stevens SR;
J Drugs Dermatol; 2008 Mar; 7(3):245-53. PubMed ID: 18380206
[TBL] [Abstract][Full Text] [Related]
38. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy.
Gordon KB; Gottlieb AB; Leonardi CL; Elewski BE; Wang A; Jahreis A; Zitnik R
J Dermatolog Treat; 2006; 17(1):9-17. PubMed ID: 16467018
[TBL] [Abstract][Full Text] [Related]
39. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
40. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety.
Yamauchi PS; Gindi V; Lowe NJ
Dermatol Clin; 2004 Oct; 22(4):449-59, ix. PubMed ID: 15450340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
